Cereno Scientific

“Nordic Life Science Days is an important platform for engaging with potential partners and investors, and we are pleased to highlight Cereno Scientific’s progress here in the Nordics. With the recently granted FDA Fast Track designation for our lead program, CS1, and positive Phase I results from CS014, we see growing interest in our innovative approach of HDAC inhibition through epigenetic modulation. We are advancing two clinical programs with significant potential in rare cardiovascular and pulmonary diseases, and we look forward to meaningful discussions with stakeholders at NLSDays,” said Sten R. Sörensen, CEO of Cereno Scientific.

Sten R. Sörensen, CEO, will also participate in a panel discussion hosted by Business Region Gothenburg discussing Cereno Scientific’s journey from idea to scale, on October 13, at 15:00 on the Expo Stage.

To schedule a meeting with Cereno Scientific register at: https://nlsdays.com/partnering/.

The Nordic Life Science Days is the premier event for Nordic life science with delegates from biotech, medtech, finance and research sectors. Over 1,500 delegates from the Nordics and internationally joins for a valuable program and over 3,000 partnering meetings is held over two days.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications

Email:  tove.bergenholt@cerenoscientific.com

Phone: +46 73- 236 62 46

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. The company’s innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling and improvement of right heart function as observed in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, a new chemical entity with disease-modifying potential, showed favorable safety and tolerability profile in a Phase I trial. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and pulmonary hypertension.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.